[go: up one dir, main page]

MA30063B1 - Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg) - Google Patents

Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)

Info

Publication number
MA30063B1
MA30063B1 MA31047A MA31047A MA30063B1 MA 30063 B1 MA30063 B1 MA 30063B1 MA 31047 A MA31047 A MA 31047A MA 31047 A MA31047 A MA 31047A MA 30063 B1 MA30063 B1 MA 30063B1
Authority
MA
Morocco
Prior art keywords
aryluree
fcg
pyrimidinyl
inhibitors
derivatives
Prior art date
Application number
MA31047A
Other languages
English (en)
Inventor
Guido Bold
Pascal Furet
Vito Guagnano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30063B1 publication Critical patent/MA30063B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des hétéroarylarylurées de formule IA : dans laquelle les radicaux et les symboles ont les significations définies ici, l'utilisation de ces composés dans le traitement de maladies sous la dépendance de protéine-kinases, des préparations pharmaceutiques comprenant lesdites hétéroarylarylurées, des procédés de fabrication de ces nouveaux composés et des procédés de traitement comprenant l'utilisation de ces hétéroarylarylurées.
MA31047A 2005-12-21 2008-06-18 Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg) MA30063B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75271105P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
MA30063B1 true MA30063B1 (fr) 2008-12-01

Family

ID=37946774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31047A MA30063B1 (fr) 2005-12-21 2008-06-18 Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)

Country Status (22)

Country Link
US (2) US8293746B2 (fr)
EP (1) EP1976847B1 (fr)
JP (1) JP5153645B2 (fr)
KR (1) KR101406956B1 (fr)
CN (1) CN101336237B (fr)
AU (1) AU2006326989B2 (fr)
BR (1) BRPI0620408B8 (fr)
CA (1) CA2634047C (fr)
CR (1) CR10072A (fr)
EA (1) EA016438B1 (fr)
EC (1) ECSP088561A (fr)
GE (1) GEP20105074B (fr)
HN (1) HN2008000949A (fr)
IL (1) IL192093A0 (fr)
MA (1) MA30063B1 (fr)
ME (2) MEP3808A (fr)
NO (1) NO20083214L (fr)
SM (1) SMP200800041B (fr)
SV (1) SV2008002967A (fr)
TN (1) TNSN08276A1 (fr)
WO (1) WO2007071752A2 (fr)
ZA (1) ZA200805092B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MEP3808A (xx) * 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
EP2470511A1 (fr) * 2009-08-28 2012-07-04 Genentech, Inc. Composés inhibiteurs des raf kinases et leurs procédés d'utilisation
WO2011051425A1 (fr) * 2009-10-30 2011-05-05 Novartis Ag N-oxyde de 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-{6-[4-(4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin-4-yl}-1-méthyl-urée
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2512476A1 (fr) * 2009-12-18 2012-10-24 Novartis AG Procédé pour le traitement de cancers hématologiques
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
PT2821402T (pt) 2012-02-28 2019-10-02 Kotobuki Pharmaceutical Co Ltd Composto aromático heterocíclico que contém nitrogénio
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP6232630B2 (ja) * 2013-03-10 2017-11-22 国立大学法人名古屋大学 骨系統疾患治療薬及びその用途
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
EP2968551B1 (fr) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Protéines de fusion et procédés correspondants
EP2789619A1 (fr) 2013-04-12 2014-10-15 Kemotech S.r.l. Composés pharmaceutiques ayant une activité inhibitrice de l'angiogenèse
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AR098048A1 (es) 2013-10-18 2016-04-27 Eisai R&D Man Co Ltd Inhibidores de fgfr4
TR201810944T4 (tr) * 2013-10-25 2018-08-27 Novartis Ag Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
PE20160851A1 (es) 2013-12-13 2016-09-14 Novartis Ag Formas de dosificacion farmaceuticas
CA2954187C (fr) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase macrocycliques et leurs utilisations
WO2016014542A1 (fr) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'imidazolyl kinase et leurs utilisations
CA2955082A1 (fr) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Utilisations d'inhibiteurs de kinases inductibles par un sel (sik)
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (fr) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Protéines de fusion et procédés associés
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3275442B1 (fr) 2015-03-25 2021-07-28 National Cancer Center Agent thérapeutique contre le cancer du canal cholédoque
JP6431622B2 (ja) 2015-04-14 2018-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
CN108348519A (zh) * 2015-07-20 2018-07-31 台北医学大学 经氯苯取代的氮杂芳基化合物
WO2017104739A1 (fr) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique destiné au cancer du sein
US10934311B2 (en) * 2016-01-08 2021-03-02 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound used as FGFR inhibitor
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
KR20190075043A (ko) 2016-07-05 2019-06-28 더 브로드 인스티튜트, 인코퍼레이티드 비시클릭 우레아 키나제 억제제 및 그의 용도
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
TW202411220A (zh) * 2016-12-19 2024-03-16 美商雅酶股份有限公司 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法
EP3589284A4 (fr) 2017-02-28 2020-12-16 The General Hospital Corporation Utilisations de pyrimidopyrimidinones comme inhibiteurs de sik
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
CN109053592B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053594B (zh) * 2018-08-07 2020-12-18 温州医科大学 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053593B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
CN110283130B (zh) * 2019-07-05 2023-12-19 温州医科大学 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2022261160A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2025090870A1 (fr) 2023-10-27 2025-05-01 Qed Therapeutics, Inc. Infigratinib et ses métabolites destinés à être utilisés dans des méthodes de traitement d'affections du squelette

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759921A (en) * 1969-10-16 1973-09-18 Lilly Co Eli Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2386218A1 (fr) * 1999-10-07 2001-04-12 Amgen Inc. Inhibiteurs de triazine kinase
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ITMI20010528A1 (it) 2001-03-13 2002-09-13 Istituto Biochimico Pavese Pha Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche
US20020156257A1 (en) 2001-03-29 2002-10-24 Chunhua Yan Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7125997B2 (en) 2002-12-20 2006-10-24 Irm Llc Differential tumor cytotoxicity compounds and compositions
US20060004005A1 (en) 2003-09-25 2006-01-05 Sattigeri Viswajanani J Triazines derivatives as cell adhesion inhibitors
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
JP2007538063A (ja) 2004-05-20 2007-12-27 スージェン， インク． チオフェンヘテロアリールアミン
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (fr) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese
WO2006053227A2 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes modulateurs de la il-12
CA2619366A1 (fr) * 2005-08-22 2007-03-01 Amgen Inc. Composes d'uree de bis-aryle pour le traitement de maladies mediees par une proteine kinase
MEP3808A (xx) * 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
US20090062320A1 (en) * 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor

Also Published As

Publication number Publication date
CN101336237A (zh) 2008-12-31
BRPI0620408A2 (pt) 2011-11-08
ME00011A (fr) 2009-02-10
CN101336237B (zh) 2015-09-30
AU2006326989A1 (en) 2007-06-28
CR10072A (es) 2008-08-25
WO2007071752A2 (fr) 2007-06-28
EP1976847A2 (fr) 2008-10-08
JP5153645B2 (ja) 2013-02-27
IL192093A0 (en) 2008-12-29
ECSP088561A (es) 2008-07-30
JP2009520768A (ja) 2009-05-28
MEP3808A (xx) 2010-02-10
CA2634047C (fr) 2016-04-12
US8293746B2 (en) 2012-10-23
HN2008000949A (es) 2010-11-11
CA2634047A1 (fr) 2007-06-28
KR101406956B1 (ko) 2014-06-13
US20130030171A1 (en) 2013-01-31
EA200801565A1 (ru) 2008-12-30
ZA200805092B (en) 2009-09-30
BRPI0620408B8 (pt) 2021-05-25
AU2006326989B2 (en) 2011-11-24
KR20080090439A (ko) 2008-10-08
US8759517B2 (en) 2014-06-24
BRPI0620408B1 (pt) 2020-09-15
EA016438B1 (ru) 2012-05-30
EP1976847B1 (fr) 2015-06-17
WO2007071752A3 (fr) 2007-11-08
NO20083214L (no) 2008-09-01
US20080312248A1 (en) 2008-12-18
SMAP200800041A (it) 2008-07-23
SV2008002967A (es) 2011-01-24
GEP20105074B (en) 2010-09-10
SMP200800041B (it) 2009-07-14
TNSN08276A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
MA30063B1 (fr) Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA31090B1 (fr) Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
BRPI0515489A (pt) derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
HRP20060251A2 (en) Substituted oxasolidinones and their use
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
SE0104331D0 (sv) Novel compounds
HRP20041048B1 (hr) POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer